Paris, December 10, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), and tebu-bio today announced that they will join forces for the distribution of Cellectis bioresearch’s research kits in Europe. These two market leaders will pool their expertise to ensure maximum availability for these cutting-edge products.
Cellectis bioresearch will be responsible for the design and production of the targeted integration kits from its cGPS® and cGPS® Custom lines. tebu-bio will be responsible for distributing these kits to research laboratories across Europe. tebu-bio will have exclusive distribution rights for the major European markets where it has a physical presence. However the kits will remain available for purchase on the Cellectis bioresearch website (www.cellectis-bioresearch.com). The cGPS® and cGPS® Custom lines were recently launched and currently include five targeted integration kits. The variety of products available in these lines is due to expand significantly from 2010 onwards.
“We are delighted to be able to work with tebu-bio,” said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. “By pooling our scientific expertise with their commercial experience, we can look forward to rapidly expanding the network of users for our kits.” This partnership will offer Cellectis bioresearch a foothold in the academic research market, a major target in terms of the number of potential users. The first product for targeted integration in human cells is due to be launched shortly.
“The products developed by Cellectis bioresearch represent a major innovation that will be useful for a large number of laboratories,” commented Philippe Fixe, Marketing Director for tebu-bio. “They are easy to use and effective, and will perfectly complement our extensive offer.”
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with genome customization kits for rapid, efficient gene integration at a precise genomic position in a given cell type.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com
About tebu-bio
Expert in the supply and distribution of Life Sciences research reagents throughout Europe, tebubio also provides R&D contract services through their own laboratories. Their online catalogue at http://www.tebu-bio.com/ offers access to the most innovative range of over 750.000 products and lab services from world-renowned brands and manufacturers.
